What does CTIBL stand for?

Cancer Treatment-Induced Bone Loss

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Certificate in Teaching Italian to Adults Cie de Théâtre l'Impromptu de l'Assomption (French; l'Assomption, Québec) Clark-Theders Insurance Agency (Ohio) Color Television Interface Adapter (Atari 8-bit computer custom chip) Committee to Investigate Assassinations Common Training Instrumentation Architecture Computer Technology Industry Association Combustion Turbine Inlet Air Cooling (gas turbines) Concrete Technology Information Analysis Center (US DoD) Centre Technique de l'Industrie du Bois (French: Wood Industry Technical Center; Belgium)		Centro Tecnológico de la Información y de la Comunicación (Spanish: Center for the Development of Information and Communication Technologies in Asturias) Chicago Title Insurance Company China Tibet Information Center Combatant Technical Issues Conference Computational Topology in Image Context (workshop) COMSEC/TRANSEC Integrated Circuit Conseil en Technologies de l'Information et de la Communication (French: Information Technology and Communication Council) Conservation Technology Information Center Contractor Technical Information Coding Cape Town International Convention Centre (South Africa)

Samples in periodicals archive:

Over 11,000 patients are currently enrolled in denosumab oncology clinical trials testing the drug for bone loss associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

Amgen Announces Positive Top-Line Results for Denosumab Treatment of ...

Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in ...

Amgen Reports Positive Data at ASCO from Three Studies of Denosumab ...